Login / Signup

Cellular dormancy in minimal residual disease following targeted therapy.

Jason R RuthDhruv K PantTien-Chi PanHans E SeidelSanjeethan C BakshBlaine A KeisterRita SinghChristopher J SternerSuzanne J BakewellSusan E MoodyGeorge K BelkaLewis A Chodosh
Published in: Breast cancer research : BCR (2021)
Residual cancer cells surviving targeted therapy reside in a well-vascularized, desmoplastic microenvironment at both local and distant sites. These cells exist in a state of cellular dormancy that bears little resemblance to primary or recurrent tumor cells, but shares similarities with cells in which dormancy is induced by microenvironmental cues. Our observations suggest that dormancy may be a conserved response to targeted therapy independent of the oncogenic pathway inhibited or properties of the primary tumor, that the mechanisms underlying dormancy at local and distant sites may be related, and that the dormant state represents a potential therapeutic target for preventing cancer recurrence.
Keyphrases